Jaipur Nuclear & Imaging Center Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 17-12-2024
- Paid Up Capital ₹ 2.50 M
as on 17-12-2024
- Company Age 20 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 132.63%
(FY 2022)
- Profit 6829.29%
(FY 2022)
- Ebitda 436.14%
(FY 2022)
- Net Worth 301.71%
(FY 2022)
- Total Assets -40.73%
(FY 2022)
About Jaipur Nuclear & Imaging Center
The Corporate was formerly known as Galaxy Classic Bio-Tech Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Mitesh Gupta and Sakshi Gupta serve as directors at the Company.
- CIN/LLPIN
U85191RJ2004PTC019366
- Company No.
019366
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jun 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Jaipur Nuclear & Imaging Center?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mitesh Gupta  | Director | 28-Apr-2017 | Current |
| Sakshi Gupta | Director | 05-Aug-2020 | Current |
Financial Performance and Corporate Structure Insights of Jaipur Nuclear & Imaging Center.
Jaipur Nuclear & Imaging Center Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 132.63% increase. The company also saw a substantial improvement in profitability, with a 6829.29% increase in profit. The company's net worth Soared by an impressive increase of 301.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jaipur Nuclear & Imaging Center?
Unlock access to Jaipur Nuclear & Imaging Center's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Niruma Life Sciences Private LimitedActive 4 years 5 monthsMitesh Gupta and Sakshi Gupta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jaipur Nuclear & Imaging Center?
Unlock and access historical data on people associated with Jaipur Nuclear & Imaging Center, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jaipur Nuclear & Imaging Center, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jaipur Nuclear & Imaging Center's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
